Published in:
Open Access
01-12-2019 | Meningioma | Research
The clinical characteristics and molecular mechanism of pituitary adenoma associated with meningioma
Authors:
Haibo Zhu, Yazhou Miao, Yutao Shen, Jing Guo, Weiyan Xie, Sida Zhao, Wei Dong, Yazhuo Zhang, Chuzhong Li
Published in:
Journal of Translational Medicine
|
Issue 1/2019
Login to get access
Abstract
Background
Pituitary adenoma and meningioma are the most common benign tumors in the central nervous system. Pituitary adenoma associated with meningioma (PAM) is a rare disease and the clinical features and mechanisms of PAM are unclear.
Methods
We summarized the clinical data of 57 PAM patients and compared with sporadic pituitary adenoma (SPA) and sporadic meningioma (SM). 5 pituitary adenomas of PAM and 5 SPAs were performed ceRNA microarray. qRT-PCR, Western Blot, siMEN1 and rapamycin inhibition experiment were validated for ceRNA microarray.
Results
Clinical variable analyses revealed that significant correlations between PAM and female sex as well as older age when compared with SPA and significant correlations between PAM and transitional meningioma as well as older age when compared with SM. Additionally, the characteristics of PAM were significantly different for MEN1 patients. Functional experiments showed lower expression of MEN1 can upregulate mTOR signaling, in accordance with the result of ceRNA microarray. Rapamycin treatment promotes apoptosis in primary pituitary adenoma and meningioma cells of PAM.
Conclusions
MEN1 plays an important role in PAM by upregulating mTOR signaling pathway. Rapamycin represents a potential therapeutic strategy for PAM in the future.